Silverback Therapeutics

OverviewSuggest Edit

Silverback Therapeutics is a biotech company developing treatments for cancer, fibrosis, and infectious diseases. It uses ImmunoTAC technology to create therapeutic molecules that can be systemically administered to patients and act only at the sites of disease, sparing healthy tissues from unwanted side effects

TypePublic
Founded2016
HQSeattle, WA, US
Websitesilverbacktx.com

Latest Updates

Employees (est.) (Sept 2020)52
Share Price (Oct 2021)$9.4(-4%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Silverback Therapeutics

Laura Shawver

Laura Shawver

President & CEO
Naomi Hunder

Naomi Hunder

Chief Medical Officer
Russ Hawkinson

Russ Hawkinson

Senior Vice President of Finance
Valerie Odegard

Valerie Odegard

President & Chief Scientific Officer
Peter Baum

Peter Baum

Vice President of Immunology
Jill Herendeen

Jill Herendeen

Vice President of Regulatory Affairs
Show more

Silverback Therapeutics Office Locations

Silverback Therapeutics has an office in Seattle
Seattle, WA, US (HQ)
500 Fairview Ave N #600
Show all (1)

Silverback Therapeutics Financials and Metrics

Silverback Therapeutics Revenue

USD

Net income (Q1, 2021)

(18.9m)

EBIT (Q1, 2021)

(18.9m)

Market capitalization (18-Oct-2021)

327.4m

Closing stock price (18-Oct-2021)

9.4

Cash (31-Mar-2021)

374.2m

EV

(43.8m)
Silverback Therapeutics's current market capitalization is $327.4 m.
Annual
USDFY, 2018FY, 2019

General and administrative expense

3.5m2.6m

R&D expense

14.8m21.5m

Operating expense total

18.3m24.1m

EBIT

(18.3m)(24.1m)
Quarterly
USDQ1, 2021

General and administrative expense

6.6m

R&D expense

12.2m

Operating expense total

18.9m

EBIT

(18.9m)
Annual
USDFY, 2018FY, 2019

Cash

20.2m10.0m

Current Assets

20.8m10.5m

PP&E

1.8m1.3m

Total Assets

27.5m15.6m
Quarterly
USDQ3, 2020Q1, 2021

Cash

142.3m374.2m

Prepaid Expenses

4.1m

Current Assets

143.2m378.3m

PP&E

1.7m1.6m
Annual
USDFY, 2018FY, 2019

Net Income

(17.6m)(24.0m)

Depreciation and Amortization

480.0k544.0k

Accounts Payable

513.0k4.0m

Cash From Operating Activities

(16.9m)(18.9m)
Quarterly
USDQ3, 2019Q3, 2020Q1, 2021

Net Income

(17.0m)(19.9m)(18.9m)

Depreciation and Amortization

406.0k448.0k186.0k

Accounts Payable

3.5m(914.0k)2.2m

Cash From Operating Activities

(13.0m)(20.1m)(12.2m)
USDFY, 2018

Debt/Equity

-0.2 x

Debt/Assets

0.3 x

Financial Leverage

-0.8 x
Show all financial metrics

Silverback Therapeutics Operating Metrics

Q3, 2020

Lead Optimization Stage Products

1

IND-Enabling Stage Products

1

Phase I Trials Products

1
Show all operating metrics

Silverback Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Silverback Therapeutics Online and Social Media Presence

Embed Graph

Silverback Therapeutics News and Updates

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX

NEW YORK, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Silverback Therapeutics, Inc. (“Silverback” or the “Company”) (NASDAQ: SBTX).   Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980…

Silverback Therapeutics upsizes IPO, to now raise up to $200 million

Silverback Therapeutics Inc. upsized its initial public offering to 10.00 million shares, and the expected pricing of the offering increased to between $19 and $20 a share. The Seattle-based biopharmaceutical company focused on cancer treatment had said earlier this week that it was offering 6.95 m…

Silverback Therapeutics Frequently Asked Questions

  • When was Silverback Therapeutics founded?

    Silverback Therapeutics was founded in 2016.

  • Who are Silverback Therapeutics key executives?

    Silverback Therapeutics's key executives are Laura Shawver, Naomi Hunder and Russ Hawkinson.

  • How many employees does Silverback Therapeutics have?

    Silverback Therapeutics has 52 employees.

  • Who are Silverback Therapeutics competitors?

    Competitors of Silverback Therapeutics include NovoCure, Neovii and Eutilex.

  • Where is Silverback Therapeutics headquarters?

    Silverback Therapeutics headquarters is located at 500 Fairview Ave N #600, Seattle.

  • Where are Silverback Therapeutics offices?

    Silverback Therapeutics has an office in Seattle.

  • How many offices does Silverback Therapeutics have?

    Silverback Therapeutics has 1 office.